Synektik Pharmasp. z o.o.

Manufacture of pharmaceutical preparations

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2011-09-09
Share capital
10 050,00 PLN
Activity description

Synektik Pharma Sp. z o.o. is part of the Synektik Group. The Group provides medical facilities with medical technologies, robotics, radiopharmaceuticals and IT solutions.

Registered address
ul. Józefa Piusa Dziekońskiego 3, 00-728 Warszawa, Poland
Website
synektik.com.plWebsite active
Email
Email address current
Phone
Social media
Electronic delivery address
AE:PL-61568-32596-VUFGS-34

Financials

Revenue history (in m)

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue
This companyUSD 13.22mMedianUSD 782.27kAverageUSD 24.03m
Net profit
This companyUSD 2.01mMedianUSD 7.91kAverageUSD 2.59m
Operating costs
This companyUSD 10.17mMedianUSD 723.93kAverageUSD 19.92m
Assets
This companyUSD 12.07mMedianUSD 800.34kAverageUSD 29.11m

Bank accounts

Registered as a VAT taxpayer on 2011-09-14. Active

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

Real estate

TypeAmount
Land (incl. perpetual usufruct)
$98,810
Buildings and premises
$1.5M

Public aid

7 public aid cases recorded, with a total value of $870,982.

PurposeGross amount
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$11,158
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$11,568
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$11,060

European Funds

ProjectEU co-financing
Rozwój zaplecza badawczo-rozwojowego Synektik Pharma w celu opracowania nowych radiofarmaceutyków specjalnych do celowanej diagnostyki onkologicznej i neurologicznej metodą Pozytonowej Tomografii Emisyjnej (PET)
$428.7K
Wprowadzenie na rynek nowego radiofarmaceutyku 18F-fluorotymidyny (FLT) do celowanej diagnostyki onkologicznej i oceny postepów terapii.
$227.6K

Tenders

70 tenders recorded as contractor: 31 national ($4,169,254) and 39 EU ($40,406,151).

SubjectAmount
Dostawa materiałów radioizotopowych
–
Zakup i dostawa radiofarmaceutycznych produktów leczniczych stosowanych w ramach programu lekowego i poza programem oraz wyrobów medycznych
$1.4M
EZ.271.228.2025 Postępowanie o udzielenie zamówienia publicznego na dostawę wyrobów medycznych dla Wojewódzkiego Wielospecjalistycznego Centrum Onkologii i Traumatologii im. M. Kopernika w Łodzi prowadzonego w trybie przetargu nieograniczonego o wartości powyżej 10 000 000 Euro.
$2.4M

Public sector contracts

Synektik Pharma is the contractor in 7 public sector contracts, worth PLN 1.94m in total. They were signed with 4 public buyers.

Public buyerValue
5 Wojskowy Szpital Kliniczny z Polikliniką-Samodzielny Publiczny Zakład Opieki Zdrowotnej w KrakowiePLN 55,200
Świętokrzyskie Centrum Onkologii Samodzielny Publiczny Zakład Opieki Zdrowotnej w KielcachPLN 373,500
Świętokrzyskie Centrum Onkologii Samodzielny Publiczny Zakład Opieki Zdrowotnej w KielcachPLN 100,000
Centrum Onkologii Im. Prof. Franciszka Łukaszczyka w BydgoszczyPLN 9,000
Świętokrzyskie Centrum Onkologii Samodzielny Publiczny Zakład Opieki Zdrowotnej w KielcachPLN 297,600

Public procurement disputes (KIO)

Synektik Pharma has been a party to 1 case before the National Appeal Chamber (since 2022). In 1 case it joined the proceedings as a participant.

DateCase no.RoleOther partyOutcome
Jun 14, 2022KIO 1449/22Participant (on authority's side)Dolnośląskie Centrum Onkologii, Pulmonologii i HematologiiAuthority accepted the complaints

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Authorized Representatives

Przemysław Bolesław Kozanecki – President of the Management Board

Manner of representation

In the case of a one-person management board, each member of the management board acting independently. In the case of a multi-member management board, the President of the Management Board independently, or two members of the management board acting jointly, or one member of the management board acting jointly with a commercial proxy.

Ownership

OwnerSharesShare valueStake
Synektik S.A.
201$2,714.75100%

Beneficial owners

Person

Competitors

Change history

DateEvent
2021-08-12Address change
2018-08-24Share capital change
2018-07-04Share capital change
2018-05-10Address change
2018-05-10Name change

FAQ

Last updated: 2026-10-07